CXCL10 As a Biomarker Of ILD in Patients WithRA

Study Overview
=================
Brief Summary
-----------------
Rheumatoid arthritis is a chronic inﬂammatory disease that affects the joints, causing symmetric pain, stiffness, swelling, and limited motion and function of multiple joints, its ﬁbro inﬂammatory manifestations may develop in other organs.

Detailed Description
-----------------
Rheumatoid arthritis is complicated by lung manifestations, such as interstitial lung disease which is the most common cause of morbidity and mortality in rheumatoid arthritis patients. Rheumatoid arthritis-interstitial lung disease is a progressive fibrotic disease of the lung parenchyma that includes a broad spectrum of disorders such as nonspeciﬁc interstitial pneumonia, usual interstitial pneumonia , desquamative interstitial pneumonia, cryptogenic organizing pneumonia, diﬀuse alveolar damage, acute interstitial pneumonia, and lymphocytic interstitial pneumonia . Rheumatoid arthritis-interstitial lung disease in which available data indicate that dysregulated inflammatory cascades can elaborate a host of cytokines, chemokines, and growth factors that collectively promote epithelial and endothelial cell damage, angiogenesis, fibroblast differentiation/proliferation, and lung fibrosis . Given the clinical implications of putative signaling cascades involved in these processes, biomarkers that can be used to clarify disease pathogenesis and identify factors governing disease progression are clearly needed .

Official Title
-----------------
CXCL10 As a Biomarker Of Interstitial Lung Disease in Patients With Rheumatoid Arthritis

Conditions
-----------------
Interstitial Lung Disease in Patients With Rheumatoid Arthritis

Intervention / Treatment
-----------------
* Diagnostic Test: serum cxcl10 by ELISA


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult rheumatoid arthritis patients who fulfilled the 2010 American College of Rheumatology/European league against rheumatism criteria for the classification of Rheumatoid Arthritis. Adult rheumatoid arthritis patients with interstitial lung disease. Exclusion Criteria: Individuals with other autoimmune diseases (systemic lupus erythematosus, polyarteritis nodosa, dermatomyositis, scleroderma, spondyloarthritis and inflammatory bowel disease). Individuals with hepatitis, Rhinovirus infection, cerebral malaria. Individuals with colorectal carcinoma, syndrome of frailty, vetiligo.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Adult Rheumatoid Arthritis Patient with Interstitial Lung Dise<br>History taking: age, sex, disease duration, history of present illness, drug intake, past and family history. Physical examination including thorough clinical examination. Health assessment questionnaire-disability index (HAQ-DI): It is used as a subjective measure of physical function of RA patients (Pincus et al., 1983). There are 20 items in 8 categories: dressing, rising, eating, walking, hygiene, reach, grip, and usual activities (Jessica et al., 2018). | Diagnostic Test: serum cxcl10 by ELISA<br>* serum sample<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| CXCL10 As a Biomarker Of Interstitial Lung Disease in Patients With Rheumatoid Arthritis | serum level | 2 years |